Meropenem
- Generic Name
- Meropenem
- Brand Names
- Vabomere
- Drug Type
- Small Molecule
- Chemical Formula
- C17H25N3O5S
- CAS Number
- 96036-03-2
- Unique Ingredient Identifier
- YOP6PX0BAO
- Background
Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.
...
- Indication
For use as single agent therapy for the treatment of the following infections when caused by susceptible isolates of the designated microorganisms: complicated skin and skin structure infections due to Staphylococcus aureus (b-lactamase and non-b-lactamase producing, methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, vi...
- Associated Conditions
- Bacterial Infections, Complicated Intra-Abdominal Infections (cIAIs), Meningitis, Bacterial, Complicated Urinary Tract Infection caused by susceptible bacteria, Complicated skin infection bacterial
- Associated Therapies
- -
Comparative Clinical Study Between Colistin-Tigecycline Combined Therapy Versus Colistin-Meropenem Combined Therapy in Treatment of Blood Stream Infections With Multidrug-Resistant Klebsiella Pneumoniae
- First Posted Date
- 2020-07-28
- Last Posted Date
- 2020-07-29
- Lead Sponsor
- Al-Azhar University
- Target Recruit Count
- 60
- Registration Number
- NCT04489459
- Locations
- 🇪🇬
Qasr El Ainy, Cairo, Egypt
Temocillin vs Meropenem for the Targeted Treatment of Bacteraemia Resistant to Third Gen Cephalosporins
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2024-08-28
- Target Recruit Count
- 334
- Registration Number
- NCT04478721
- Locations
- 🇪🇸
Hospital Universitario de Cruces, Barakaldo, Bizkaia, Spain
🇪🇸Hospital Clínico Universitario de Santiago, Santiago de Compostela, A Coruña, Spain
🇪🇸Hospital ParcTaulí, Sabadell, Barcelona, Spain
Usage of Meropenem/Gentamicin Versus Ceftazidime/Avibactam in ARDS
- Conditions
- Interventions
- First Posted Date
- 2020-05-26
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- King Abdul Aziz Specialist Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT04402359
- Locations
- 🇸🇦
King abd el Aziz specialist hospital, Ta'if, Saudi Arabia
Ceftolozane-tazobactam Versus Meropenem for ESBL and AmpC-producing Enterobacterales Bloodstream Infection
- Conditions
- Interventions
- First Posted Date
- 2020-01-23
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- The University of Queensland
- Registration Number
- NCT04238390
- Locations
- 🇦🇺
Sir Charles Gairdner, Perth, Western Australia, Australia
🇦🇺Fiona Stanley Hospital, Perth, Western Australia, Australia
🇸🇦King Abdulaziz Medical City, Riyadh, Saudi Arabia
Optimized Antibiotic Therapy in Patients With Subarachnoid Haemorrhage (ES) and Cerebral Haemorrhage (EC)
- First Posted Date
- 2019-10-18
- Last Posted Date
- 2021-07-21
- Target Recruit Count
- 104
- Registration Number
- NCT04132115
- Locations
- 🇮🇹
Anesthesiology and Intensive Care Clinic - Department of Medicine - ASUIUD, Udine, Italy
🇮🇹Terapia Intensiva 1, Udine, Italy
Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae
- Conditions
- Interventions
- First Posted Date
- 2019-03-27
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Universidad del Norte
- Target Recruit Count
- 198
- Registration Number
- NCT03891433
- Locations
- 🇨🇴
Universidad del Norte´s Hospital, Soledad, Atlantico, Colombia
PK/PD and Clinial Outcomes of Beta-lactams in ICU Patients
- Conditions
- Interventions
- First Posted Date
- 2019-02-28
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- Prince of Songkla University
- Target Recruit Count
- 102
- Registration Number
- NCT03858387
- Locations
- 🇹🇭
Faculty of Medicine, Prince of Songkla University, Thailand, Hat Yai, Songkla, Thailand
Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections
- Conditions
- Interventions
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Venatorx Pharmaceuticals, Inc.
- Target Recruit Count
- 661
- Registration Number
- NCT03840148
- Locations
- 🇺🇸
Site 184001, La Mesa, California, United States
🇺🇸Site 184002, Chula Vista, California, United States
🇧🇬Site 110003, Ruse, Bulgaria
Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)
- Conditions
- Interventions
- First Posted Date
- 2019-02-05
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 268
- Registration Number
- NCT03830333
- Locations
- 🇨🇳
Wuxi No.2 People's Hospital ( Site 0050), Wuxi, Jiangsu, China
🇨🇳Navy General Hospital ( Site 0009), Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Guangzhou Medical University ( Site 0026), Guangzhou, Guangdong, China
suPAR to Guide Antibiotics in Emergency Department
- First Posted Date
- 2018-10-24
- Last Posted Date
- 2020-07-30
- Lead Sponsor
- Hellenic Institute for the Study of Sepsis
- Target Recruit Count
- 220
- Registration Number
- NCT03717350
- Locations
- 🇬🇷
3rd Department of Internal Medicine at SOTIRIA General Hospital of Chest Diseases of Athens, Athens, Greece
🇬🇷4th Department of Internal Medicine, ATTIKON University Hospital, Athens, Attiki, Greece
🇬🇷1st Department of Internal Medicine of G. GENNIMATAS General Hospital, Athens, Greece
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.